Results of Surgery in Lung Cancer – A Retrospective Study of a Single Center Experience

Authors

  • Rita Costa Department of Cardiothoracic Surgery, Centro Hospitalar São João, Porto, Portugal https://orcid.org/0000-0001-7831-8711
  • Fátima Aires Department of Radiation Oncology, Centro Hospitalar São João, Porto, Portugal
  • José Máximo Department of Cardiothoracic Surgery, Centro Hospitalar São João, Porto, Portugal
  • Diana Pissarra Department of Cardiothoracic Surgery, Centro Hospitalar São João, Porto, Portugal
  • João Maciel Department of Cardiothoracic Surgery, Centro Hospitalar Universitário de Lisboa Central-Hospital Santa Marta, Lisboa, Portugal
  • Margarida Marques Department of Radiation Oncology, Centro Hospitalar São João, Porto, Portugal
  • Pedro Fernandes Department of Cardiothoracic Surgery, Centro Hospitalar São João, Porto, Portugal
  • Paulo Pinho Department of Cardiothoracic Surgery, Centro Hospitalar São João, Porto, Portugal

DOI:

https://doi.org/10.48729/pjctvs.212

Keywords:

Lung Cancer, Lobectomy, Overall Survival, Thoracic Surgery

Abstract

Objectives: Surgery provides the best chance for cure in patients with non-small-cell lung cancer stage I or II, but only a small portion of all new cases diagnosed are eventually suitable for surgical resection. Our goal was to appraise the surgical outcomes including survival and progression rates in patientswith histological diagnosis of lung cancer.

Methods: Between 1st August 2012 and 30th June 2018, the patients with histological lung cancer diagnosis that underwent surgical resection with a curative intent at the department of Cardiothoracic Surgery of Centro Hospitalar Univer- sitário de São João were included.

Results: The majority of patients were pathological stage I and the most performed surgery was a lobectomy (90.6%). The hospitality mortality was 1,3% and the rate of complication was 26,1%. Patients with forced expiratory volume in 1 second (FEV1) less than 80% had higher (statistically significant difference) frequency of complications. Active smokers, Eastern Co- operative Oncology Group Performance Status (ECOG PS)value different than 0 and FEV1 inferior to 80% had a higher mean length of drainage and higher mean length of stay (statistically significant difference). The overall survival was 92,6% at 1 year, 87,7 % in 2 years and 79,1% in 5 years. The overall survival according to pathological stages were similar when compared with the literature.

Conclusions: Ours results are similar to international centers and we should be more alert to preoperative assessment.

Downloads

Download data is not yet available.

References

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.. Mayo Clin Proc. 2008;83(5):584-594. doi:10.4065/83.5.584

Le Chevalier T. Adjuvant chemotherapy for resectable non-small cell lung cancer: where is it going? Ann Oncol. 2010;21Suppl 7:vii196-vii198. doi:10.1093/annonc/mdq376

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the stage grouping in the forthcoming (8th) edition of the TNM classification of lung cancer. J ThoracOncol. 2016;11(1):39-51. doi:10.1016/j. jtho.2015.09.009

National Comprehensive Cancer Network. Guidelines Non- Small Cell Lung Cancer. Version 4.2021.

Direcção Nacional de Saude, Relatório do Programa Nacional para a Prevenção e Controlo do Tabagismo 2019

Rami-Porta R, Tsuboi M. Sublobar resection for lungcancer. EurRespir J. 2009;33(2):426-435. doi:10.1183/09031936.00099808

Falcoz PE, Puyraveau M, Thomas PA, Decaluwe H, Hürtgen M, Petersen RH et al. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg. 2016;49(2):602-609. doi:10.1093/ejcts/ezv154

Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE 2nd, Landreneau RJ et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial Ann Thorac Surg. 2006;81(3):1013-1020. doi:10.1016/j. athoracsur.2005.06.066

Marino KA, Little MA, Bursac Z, Sullivan JL, Klesges R, Weksler B. Operating on Patients Who Smoke: A Survey of Thoracic Surgeons in the United States. Ann Thorac Surg. 2016;102(3):911-916. doi:10.1016/j.athoracsur.2016.03.076

P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J. Vansteenkiste et al. Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21Suppl 5:v103-v115. doi:10.1093/annonc/mdq207

Imai H, Kaira K, Minato K. Clinical significance of post-progression survival in lung cancer. Thorac Cancer. 2017;8(5):379- 386. doi:10.1111/1759-7714.12463

Downloads

Published

05-10-2022

How to Cite

1.
Costa R, Aires F, Máximo J, Pissarra D, Maciel J, Marques M, Fernandes P, Pinho P. Results of Surgery in Lung Cancer – A Retrospective Study of a Single Center Experience. Rev Port Cir Cardiotorac Vasc [Internet]. 2022 Oct. 5 [cited 2024 Jun. 13];29(3):29-34. Available from: https://pjctvs.com/index.php/journal/article/view/212

Issue

Section

Original Articles

Categories

Most read articles by the same author(s)

1 2 3 > >> 

Similar Articles

You may also start an advanced similarity search for this article.